H.C. Wainwright Remains a Buy on Replimune Group Inc (REPL)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Replimune Group Inc (REPL) today and set a price target of $26.00. The company’s shares closed last Monday at $13.40.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -14.1% and a 24.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Turning Point Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Replimune Group Inc with a $25.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.25 and a one-year low of $8.88. Currently, Replimune Group Inc has an average volume of 36.03K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.